A 2015 meta-analysis of 79 studies found a 30 percent or greater reduction of pain with the use of cannabinoids compared to placebos.

An analysis of a decade of randomized, double-blind placebo-controlled clinical trials on cannabis for treating pain concluded cannabis should be a first line treatment for patients with painful neuropathy and other serious and debilitating symptoms, who often do not respond to other available medications.

Medical Cannabis as Substitute for Opiates A growing body of evidence supports the use of medical cannabis as a substitute and adjunct to prescription opiates in the treatment of chronic pain.

A study in the Clinical Journal of Pain followed 176 chronic pain patients in Israel over seven months. Researchers found that 44 percent of them stopped taking prescription opioids within seven months after starting medical cannabis.

Patients cited reasons for using cannabis instead of pharmaceutical drugs: 65% reported less adverse side effects, 57% cited better symptom management, and 34% found that cannabis had less withdrawal potential than their other medications.

A goal of NanoSphere Health Sciences is to help break the pain killerepidemicNanoSphere Health is introducing a series cannabis extract products for relieving pain and inflammation with our clinical-tested, patent-pending NanoSphere Delivery System™. They include both transdermal and intraoral formulations. And will be sold with our precision-metered, microliter dose packaging system, which allows for standardized dosing and consistent usage. They represent a promising alternative to opioid drugs and solution to help reduce the morbidity and mortality associated with prescription opioid use and abuse.